Mexylor (Lormetazepam)

Lormetazepam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. By acting as a positive allosteric modulator, it increases chloride ion flow into neurons, producing a calming effect that reduces brain activity and facilitates sleep.

The specific dose of Mexylor is determined by the prescribing clinician based on the patient’s age, health status, and severity of insomnia. Physicians typically start with the lowest effective dose and adjust as needed, following local prescribing guidelines.

Safety data for lormetazepam in pregnancy and lactation are limited. Because benzodiazepines may cross the placenta and appear in breast milk, the drug is generally avoided unless the potential benefit outweighs the risk. Consultation with a healthcare professional is essential.

To order Mexylor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mexylor belongs to the benzodiazepine class, offering rapid onset of sleep but a higher potential for dependence compared with non‑benzodiazepine hypnotics such as zolpidem. It is generally reserved for short‑term use, whereas newer agents may be preferred for longer‑term management.

Store Mexylor at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mexylor is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. It is usually taken shortly before bedtime, and patients should avoid taking it with or after a heavy meal that might delay absorption.

The most serious risks include the development of physical dependence, withdrawal symptoms upon abrupt discontinuation, respiratory depression—especially when combined with other depressants—and rare but severe allergic reactions. Monitoring for these effects is essential during therapy.

Mexylor should be avoided in patients with known hypersensitivity to lormetazepam or other benzodiazepines, those with severe respiratory insufficiency, acute narrow‑angle glaucoma, or a history of substance dependence. Caution is also advised for the elderly and individuals with hepatic impairment.